News Image

Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Provided By GlobeNewswire

Last update: Oct 14, 2025

- Petosemtamab in combination with FOLFOX /FOLFIRI (1L and 2L mCRC) and as monotherapy (3L+ mCRC), demonstrates antitumor activity and a manageable safety profile

Read more at globenewswire.com

MERUS NV

NASDAQ:MRUS (11/28/2025, 3:51:48 PM)

After market: 96.14 0 (0%)

96.14

+0.05 (+0.05%)



Find more stocks in the Stock Screener

Follow ChartMill for more